Efficacy and Safety of Normoxic Allogenic Umbilical Cord Mesenchymal Stem Cells Administered as Adjuntive Treatment to Standard Treatment in Severe Patients With COVID-19 (UCMSC)

NCT05132972 Phase 2/Phase 3 UNKNOWN

This study is conducted to assess the efficacy and safety of stem cells as adjunctive treatment for severe COVID-19 patients. Here, we want to study whether the administration of mesenchymal stem cells are safe and able to relieve some of the COVID-19 symptoms

Details

Lead sponsor	Kementerian Riset dan Teknologi / Badan Riset dan Inovasi Nasional, Indonesia
Phase	Phase 2/Phase 3
Status	UNKNOWN
Enrolment	42
Start date	2021-01-17
Completion	2021-11

Conditions

• Covid 19

Interventions

• Normoxic Allogenic UCMSC
• Normal saline solution

Primary outcomes

• Duration of hospital stay — 20 - 24 days
  Number of days since patient was administered until discharge in hospitals

Countries

Indonesia